AIM: To assess the efficacy of intravenous @entity786 pulse therapy for refractory @entity29 ( @entity29 ). METHODS: We included in our cohort eight @entity1 with (moderate/severe) steroid refractory @entity29 (4 with @entity31 and 4 with @entity30 ). They all received 6 cycles of intravenous @entity786 (800 mg) per month. RESULTS: @entity1 entered into remission after the second/third @entity786 pulse. Disease activity decreased. There were no side effects and @entity137 . All the @entity1 went into long lasting remission. All @entity30 @entity1 and 3 of 4 @entity31 @entity1 achieved complete remission. One @entity1 with @entity31 showed an impressive clinical response but did not enter into remission. For the maintenance, @entity1 with @entity30 were treated with @entity1499 (15 mg/wk) and @entity1 with @entity31 were treated with @entity500 (2.5 mg/kg body weight/d). CONCLUSION: Remission was maintained in all @entity1 for 6 mo on the average. The drug was well tolerated. These findings suggest that aggressive immunosuppressive therapy may be useful in some refractory @entity1 and further controlled study should be considered in order to fully evaluate this type of treatment as a potential therapy for @entity29 .

Pulse XXXX therapy for @entity29 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity500 :: ('MESH:D001379', 'Chemical') :: ['azathioprine'] @entity31 :: ('MESH:D003093', 'Disease') :: ['ulcerative colitis'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity29 :: ('MESH:D015212', 'Disease') :: ['inflammatory bowel disease', 'IBD'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate'] @entity30 :: ('MESH:D003424', 'Disease') :: ["Crohn's disease"]
@entity786 :: (MESH:D003520,Chemical) :: ['cyclophosphamide']
